Disclaimer & Background
This pocket guide will help serve as a reference tool for clinicians setting a patient’s Peritoneal Dialysis (PD) prescription.
The information published in this update is for general and educational purposes only. This information is in no way meant to be a substitute for medical treatment and may not be construed as medical advice, diagnosis or treatment. No action or inaction should be taken based solely on the information provided in this update. Instead, patients should consult with appropriate health professionals on any matter relating to their health and well-being. If you have any questions or concerns about peritoneal dialysis treatment, you should contact your healthcare provider. You should never delay seeking medical advice, disregard medical advice, or discontinue medical treatment because of information provided in this update.
Baxter has made all reasonable efforts to ensure that all information provided through this update is accurate at the time of inclusion; however, Baxter make no assurances as to the accuracy, currency or completeness of the content provided in this update.
DISCLAIMER OF WARRANTIES AND LIMITATION OF LIABILITY. THIS UPDATE IS PROVIDED BY BAXTER ON AN “AS IS” AND “AS AVAILABLE” BASIS. BAXTER MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, AS TO THE INFORMATION, CONTENT, OR MATERIALS INCLUDED IN THIS UPDATE. YOU EXPRESSLY AGREE THAT YOUR USE OF THIS UPDATE IS AT YOUR SOLE RISK. BAXTER DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. BAXTER WILL NOT BE LIABLE FOR ANY DAMAGES OF ANY KIND ARISING FROM THE USE OF THIS UPDATE, INCLUDING, BUT NOT LIMITED TO DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, AND CONSEQUENTIAL DAMAGES.
Sample dialysis prescriptions are based on Volume of Urea Distribution (Vurea), Residual Kidney Function (RKF) and Peritoneal Membrane Type. The sample prescriptions are intended as an aid in achieving recommended clearance goals; however, other prescription options may also exist.
If a patient develops any of the following: uremic symptoms, decline in nutritional status and/or decreased measured clearances, then a more precise prescription based on patient-specific parameters and using prescription management software is recommended.
Peter G. Blake, MB, FRCPC
John M. Burkart, MD
Catherine A. Firanek, BSN, MBA
Maggie Gellens, MD
Thomas A. Golper, MD, FACP
Audrey M. Hutchcraft, MS
Pranay Kathuria, MD, FACP, FASN
James A. Sloand, MD, FACP
Beth M. Trapani, BSN, CNN
Important information on the Extraneal (Icodextrin) PD Solution